News | November 20, 2008

Biomarkers Connect Pathway Signaling to Adverse Outcome in Brain Tumor Patients

November 20, 2008 – In the most comprehensive correlative analysis of biomarker data for glioblastoma multiforme patients treated with an epidermal growth factor receptor (EGFR) inhibitor, RTOG investigators identified a subset of patients who had significantly shorter survival times when treated with the anti-EFGR therapy according to new research from the Radiation Therapy Oncology Group (RTOG) presented at the Society for Neuro-Oncology 13th Annual Meeting in Lake Las Vegas, NV.

“Although RTOG investigators did not find a survival advantage when they added gefitinib, an EGFR inhibitor, to standard radiotherapy for glioblastoma multiforme patients, we have identified a subset of patients that fare significantly worse,” said lead author Arnab Chakravarti, M.D., of Massachusetts General Hospital, MA. “We hope that an analysis of a larger panel of markers will identify subsets of patients who respond to EGFR therapy, but each result adds to our understanding of this disease.”

The initial analysis of RTOG 0211, a phase I/II trial of gefitinib given during and for 18 months after standard radiotherapy for glioblastoma multiforme (GBM) patients, showed that gefitinib was generally well tolerated but that survival times were not significantly improved compared to historical controls. A secondary analysis of study data is attempting to identify molecular subgroups of GBM patients that are likely to benefit from anti-EGFR therapies. Tissue microarrays generated from blocks prospectively collected on 74 of the 148 patients entered on RTOG 0211 were used to analyze the predictive values of 12 molecules integral to EGFR signaling. Using this molecular data, a multivariate risk model was developed using both clinical and molecular data that appears to identify distinct populations of GBM patients who may derive an overall survival benefit from the addition of Gefitinib to radiation in the upfront setting. This data strongly highlights activation of the phosphoinositol 3-kinase (PI3K) pathway at various junctions as a major resistance mechanism to gefitinib in GBMs. The results of this study may not only aid clinicians in selecting appropriate GBM patients for anti-EGFR therapies, but may also shed light into the basic mechanisms leading to treatment resistance in these most devastating tumors.

“RTOG biomarker investigations are providing new insights into the complex mechanisms of tumor growth and drug resistance,” said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis professor and chair of the Department of Radiation Oncology in the Emory School of Medicine and chief medical officer of the Emory Winship Cancer Institute. “The group’s repository of biospecimen material collected on thousands of brain tumor patients at hundreds of North American facilities is an invaluable resource for RTOG and the scientific community.”

For more information: www.rtog.org

Related Content

Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Varian Halcyon Commissioned at MedStar Southern Maryland Hospital Center With IBA's myQA Halo
News | Quality Assurance (QA) | April 04, 2019
IBA (Ion Beam Applications S.A.) announced the successful commissioning of the Varian Halcyon at the Radiation Oncology...
Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill. Interview with Mark Pankuch, Ph.D.

Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill.
 

Feature | April 02, 2019 | Dave Fornell, Editor and A.J. Connell
April 2, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine w
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...